Positive topline phase 3 maestro-nafld-1 data demonstrate resmetirom was safe, well-tolerated and provided statistically significant improvements in key measures of liver and cardiovascular health

Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient maestro-nafld-1 safety study were achieved and demonstrate that resmetirom:

MDGL Ratings Summary

MDGL Quant Ranking